Pillebout Evangéline
Nephrology and Renal Transplant Unit, St Louis Hospital, 1 Avenue Claude Vellefaux 75010, Paris, France.
Semin Nephrol. 2024 Sep;44(5):151571. doi: 10.1016/j.semnephrol.2025.151571. Epub 2025 Mar 11.
IgA vasculitis (IgAV) is considered a systemic form of IgA nephropathy (IgAN). The two diseases share similar geographic and ethnic distribution, along with common variants in genetic association studies. The pathophysiology of IgAN and IgA vasculitis nephritis (IgAVN) can be explained by the four-hit hypothesis. Key molecules involved at each step in both diseases were evaluated as diagnostic and prognostic biomarkers with many common factors, most prominently serum galactose-deficient IgA1. On kidney biopsy, the two diseases are indistinguishable, and the established histological Oxford classification for IgAN will soon be validated for IgAVN. Chronic lesions (segmental glomerulosclerosis and tubular atrophy / interstitial fibrosis) seem more frequent in IgAN, while proliferative lesions (endocapillary hypercellularity and crescents) are more frequent in IgAVN, which could explain the worse IgAN renal prognosis. Due to characteristic skin rash, IgAVN patients are diagnosed precociously. Conversely, the frequent absence of overt clinical signs in IgAN leads to a delayed diagnostic kidney biopsy in the disease evolution, which explains the chronic pathologic lesions. From a therapeutic perspective, while impressive advances have been made in recent years for IgAN, there is a glaring lack of evidence-based guidelines for the treatment of IgAVN. Large therapeutic clinical studies are required, and future IgAN trials should include IgAVN.
IgA血管炎(IgAV)被认为是IgA肾病(IgAN)的一种全身性形式。这两种疾病在地理和种族分布上相似,并且在基因关联研究中有共同的变异。IgAN和IgA血管炎肾炎(IgAVN)的病理生理学可以用四击假说来解释。在这两种疾病的每个步骤中涉及的关键分子都被评估为具有许多共同因素的诊断和预后生物标志物,最突出的是血清半乳糖缺乏IgA1。在肾活检中,这两种疾病无法区分,并且已建立的IgAN组织学牛津分类法很快将在IgAVN中得到验证。慢性病变(节段性肾小球硬化和肾小管萎缩/间质纤维化)在IgAN中似乎更常见,而增殖性病变(毛细血管内细胞增多和新月体)在IgAVN中更常见,这可以解释IgAN较差的肾脏预后。由于特征性皮疹,IgAVN患者诊断较早。相反,IgAN中经常没有明显的临床体征导致在疾病进展中诊断性肾活检延迟,这解释了慢性病理病变。从治疗角度来看,虽然近年来IgAN取得了令人瞩目的进展,但IgAVN治疗缺乏基于证据的指南。需要进行大型治疗性临床研究,未来的IgAN试验应包括IgAVN。